A Trial of HRS4800 Tables in Healthy Male Subjects

A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Effect of Food on the Pharmacokinetics of HRS4800 in Healthy Male Participants

This is a single-site study to evaluate the safety, tolerability and pharmacokinetics (PK) of single dose administration of HRS4800, and the effect of food on the PK of HRS4800 in healthy male subjects.

Study Overview

• Status: Completed
• Conditions: Pain
• Intervention / Treatment: Drug: HRS4800 tablets; Drug: Placebo tablets

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • Western Australia
    • Nedlands, Western Australia, Australia
      • Linear Clinical Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Able to understand the purposes and risks of the trial and comply with all study procedures before entering the trial, and provide signed informed consent.
• Male aged between 18 years and 55 years at screening, inclusive.
• Total body weight ≥50 kg at screening, and body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive.
• Agree to practice true abstinence; be surgically sterilised (performed at least 6 months prior and documented to no longer produce sperm - verbal confirmation through medical history review acceptable); or agree to use a condom if sexually active with a female partner of childbearing potential for at least 3 months after dosing.
• No clinically significant abnormalities in medical history, general physical examination, vital signs, laboratory tests (hematology, urinalysis, blood chemistry, coagulation function), and ECG, as determined by the investigator. Male aged between 18 years and 55 years at screening, inclusive.

Exclusion Criteria:

• History of severe digestive system disease or having a digestive disease currently within a month of screening or before first dosing, and may affect drug absorption or have safety risks.
• Severe infections, injuries or surgeries within 3 months of screening or before first dosing, or plan to undergo any surgeries during the trial.
• Use of any medicine affecting liver metabolism within 1 month of screening (see Appendix 1); use of any prescription medications within 14 days or 5 half-lives prior to dosing, use of any over-the-counter medicine or herbal products within 7 days prior to dosing; intention to use any other medicine during the trial.
• Whole blood donation or loss of more than 200 mL of blood within 1 month prior to dosing; or blood donation or loss of more than 400 mL of blood within 3 months prior to dosing; or plasma donation within 14 days prior to dosing; or received blood within 8 weeks prior to dosing.
• History of allergy to the study drug or any component of it.
• History of regular alcohol consumption in the past 1 month exceeding an average weekly intake of 21 standard drinks: 1 drink=5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor).
• Subject has used more than 5 tobacco or nicotine-containing products per day in the 6 months prior to dosing and is unable to refrain from use of such products from at least 48 hours prior to check-in through to the final study visit.
• Treatment with an investigational drug within 30 days (or 5 half-lives, whichever is longer) of dosing.
• History of drug abuse within 2 years prior to screening.
• Other conditions or laboratory abnormality that may increase the risk associated with study participation or IP administration or interfere with the interpretation of study results and, at the discretion of the investigator, makes the subject inappropriate for entry into this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo tablets	Drug: Placebo tablets; single oral administration
Experimental: HRS4800 tablets cohort 1; Part 1 - HRS4800 Single Ascending Dose	Drug: HRS4800 tablets; single oral administration
Experimental: HRS4800 tablets cohort 2; Part 1 - HRS4800 Single Ascending Dose	Drug: HRS4800 tablets; single oral administration
Experimental: HRS4800 tablets cohort 3; Part 1 - HRS4800 Single Ascending Dose	Drug: HRS4800 tablets; single oral administration
Experimental: HRS4800 tablets cohort 4; Part 1 - HRS4800 Single Ascending Dose	Drug: HRS4800 tablets; single oral administration
Experimental: HRS4800 tablets cohort 5; Part 2 - HRS4800 Food Effect	Drug: HRS4800 tablets; single oral administration

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part 1 - HRS4800 Single Dose Escalation - Safety	• Safety: Incidence and severity of adverse events (AEs), vital signs (pulse rate, respiratory rate, blood pressure, body temperature), physical examination, laboratory tests, electrocardiogram (ECG), etc.	14 days
Part 2 - HRS4800 Food Effect	• PK parameters of HRS4800 and its active drug SHR175593 in plasma: AUC0-t	21 days
Part 2 - HRS4800 Food Effect	• PK parameters of HRS4800 and its active drug SHR175593 in plasma: AUC0-∞	21 days
Part 2 - HRS4800 Food Effect	• PK parameters of HRS4800 and its active drug SHR175593 in plasma: Tmax、	21 days
Part 2 - HRS4800 Food Effect	• PK parameters of HRS4800 and its active drug SHR175593 in plasma: Cmax	21 days
Part 2 - HRS4800 Food Effect	• PK parameters of HRS4800 and its active drug SHR175593 in plasma: t1/2、CL/F、Vz/F.	21 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part 1 - HRS4800 Single Dose Escalation - PK	• PK parameters of HRS4800 and its active drug SHR175593 in plasma: AUC0-t	14 days
Part 1 - HRS4800 Single Dose Escalation - PK	AUC0-∞、	14 days
Part 1 - HRS4800 Single Dose Escalation - PK	Tmax	14 days
Part 1 - HRS4800 Single Dose Escalation - PK	Cmax	14 days
Part 1 - HRS4800 Single Dose Escalation - PK	t1/2	14 days
Part 1 - HRS4800 Single Dose Escalation - PK	CL/F、Vz/F.	14 days

Collaborators and Investigators

• Sponsor: Atridia Pty Ltd.
• Investigators: Study Director: Na Li, Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Study record dates

Study Major Dates

• Study Start (Actual): November 12, 2020
• Primary Completion (Actual): September 20, 2021
• Study Completion (Actual): September 20, 2021

Study Registration Dates

• First Submitted: September 16, 2020
• First Submitted That Met QC Criteria: September 27, 2020
• First Posted (Actual): October 5, 2020

Study Record Updates

• Last Update Posted (Actual): March 31, 2022
• Last Update Submitted That Met QC Criteria: March 28, 2022
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Other Study ID Numbers: HRS4800-I-101-AUS

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No